

Divisions of Clinical Chemistry and Hematopathology Department of Pathology and Laboratory Medicine MacKenzie Building 5788 University Avenue Halifax, Nova Scotia B3H 1V8

Tel: 902 473 6868 Fax: 902 473 2123

## **MEMORANDUM**

## IMPORTANT INFORMATION FOR ALL USERS OF CDHA LABORATORIES

**To:** Capital Health Clinics and Physicians Nova Scotia District Laboratories

From: Dr. Manal Elnenaei, Dr. Amy Lou, Ms. Shauna Thompson, Ms. Roxanna Saulnier, Ms. Cindy

Andrews, Mr. Eugene Smith, Dr. Irene Sadek, Dr. Bassam A. Nassar Divisions of Clinical Chemistry and Hematopathology, Capital health

**Date:** March 28, 2014

**RE:** Implementation of New Analyzers at Community-based Laboratories

The Division of Clinical Chemistry in the Community-based Laboratories (Dartmouth General Hospital [DGH], Hants Community Hospital [HCH] and Cobequid Community Health Centre [CCHC] will be replacing its present Chemistry analyzers (Beckman Coulter Inc.) for **routine blood and fluid chemistries and therapeutic drugs** with analyzers from Abbott Diagnostics (this does not include endocrine, immunology or microbiology testing). The implementation date for this will take place as follows:

Dartmouth General Hospital: April 6, 2014
Hants Community Hospital: April 14, 2014
Cobequid Community Health Centre: April 23, 2014

## Hence, please be alerted to the following:

- The QEII Health Sciences Centre (VGH and HI) will not be changing over yet to the new analyzers until June (a memorandum will be sent in advance) and will continue to provide the current services.
- There are differences in the references ranges between the current and new analyzers for a number of assays, and you will need to be vigilant to this, particularly when comparing results from the QEII HSC and the different Community-based sites during the transition period (DGH, HCH and CCHC). Please review the reference ranges stated in each report prior to making your clinical decisions.
- In the initial stages of this transition there may be some delays in the turn-around times of analysis, but every effort will be made to minimize the impact of this on patient care.

If you have any queries or concerns on this matter, please contact Dr. Elnenaei at 902 473 5194, Dr Lou at 902 473 1528, Dr. Nassar at 902 473 2225 or Dr. Sadek at 902 473 8471.

We thank you for your attention.

CC. Ms. Fran O'Brien, Dr. J. Godfrey Heathcote